Skip to main content

Advertisement

Table 1 Comparison of the different variables between NAb- and NAb + patients

From: Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis

  NAb- (n = 136) NAb + (n = 39) p
Female sex 95 (69.9%) 35 (89.7%) 0.012
Mean age at MS diagnosis (years +/- SEM) 33.8 +/- 0.9 35.2 +/- 1.5 0.48
Mean age at treatment initiation (years +/- SEM) 35.5 +/- 0.9 37.3 +/- 1.6 0.32
Mean duration of MS course (years +/- SEM) 5.3 +/- 0.5 4.9 +/- 0.9 0.66
Mean EDSS at inclusion consultation (+/- SEM) 1.7 +/- 0.1 1.8 +/- 0.2 0.66
Mean ΔEDSS* (+/- SEM) +0.1 +/- 0.1 +0.4 +/- 0.1 0.035
Mean number of relapse before inclusion consultation (+/- SEM) 2.4 +/- 0.1 2.4 +/- 0.2 0.98
Mean number of relapse between inclusion and follow-up consultations (+/- SEM) 0.6 +/- 0.1 1.0 +/- 0.2 0.016
Number of non-responder patients 69 (50.7%) 27 (69.2%) 0.041
Mean MFIS score (+/- SEM) 34.2 +/- 1.7 47.3 +/- 2.9 0.0002
Number of fatigue patients 69 (50.7%) 31 (79.5%) 0.0014
Mean MADRS score (+/- SEM) 3.6 +/- 0.4 4.8 +/- 0.7 0.14
Mean MSTCQ score (+/- SEM) 7.2 +/- 0.4 5.9 +/- 0.8 0.086
IFNβ type:    
- Intramuscular IFNβ-1a 25 (18.5%) 3 (7.9%) 0.21
- Subcutaneous IFNβ-1a 77 (57%) 22 (57.9%)  
- Subcutaneous IFNβ-1b 33 (24.4%) 13 (34.2%)  
  1. *ΔEDSS = EDSS at the follow-up consultation – EDSS at the inclusion consultation.